* Study met primary safety endpoint; administration was well tolerated, with

    no serious adverse events observed
  * Early and clinically meaningful improvement from baseline in mean CAPS-5
    total score (29.5 point reduction at week 12), with change from baseline in
    mean SDS total score (14.4 point reduction at week 12)
  * 81.8% response (reduction of >= 15 points in CAPS-5 score), 63.6% remission
    (total CAPS-5 = 15-point improvement on CAPS-5 score, was 81.8% at week 4

and 77.3% at week 12. Remission, as defined by CAPS-5 total score of Â